Chemical Biology and Drug Design

MARCH 14, 2025

Drug-membrane interactions can affect the apparent binding stoichiometry and affinity, as well as the kinetics of ligands for a particular target, which is important for the extrapolation to pharmacokinetic studies.

Fragment Screening 100

Fragment Screening Pharmacokinetics Drugs Marketing 100

ASPET

JUNE 10, 2024

The objective of this study was to evaluate the systemic pharmacokinetics and mechanisms that influence the CNS distribution of WSD0628, a novel and potent ATM inhibitor, in the mouse. Thus, WSD0628 has favorable pharmacokinetic properties and potential for further exploration to determine the PK-PD-efficacy relationship in CNS tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

Chemical Biology and Drug Design

FEBRUARY 6, 2025

In general, existence of sp 3 -O slightly outperforms sp 2 -O, which is associated with balancing various factors such as flexibility, solubility, stability, and pharmacokinetics, in addition to activity and selectivity. The analysis focuses on various types of oxygen atoms, including sp 3 , sp 2 -hybridized, ring, and nonring.

FDA Approval 100

FDA Approval FDA Small Molecule Pharmacokinetics 100

Chemical Biology and Drug Design

JUNE 8, 2023

The co-administration of cryptotanshinone with ophiopogonin D induced pharmacokinetic interaction prolonging the systemic exposure and improving metabolic stability of cryptotanshinone. Abstract Cryptotanshinone and ophiopogonin D are sourced from herbs with similar indications.

Pharmacokinetics 100

Pharmacokinetics Metabolic Stability Research 100

Molecular Design

MARCH 31, 2019

Controllability of exposure is the focus of pharmacokinetic optimization and I recently became aware of an exciting new development that will surely reshape the pharmacokinetic field and transform drug discovery beyond all recognition.

Pharmacokinetics 52

Pharmacokinetics Treatment Drugs 52

Broad Institute

OCTOBER 29, 2024

So the team turned their attention to optimizing the pharmacokinetic profile of BRD-810 to preserve its ability to kill tumor cells without negatively affecting heart cells.

Drugs 133

Drugs Small Molecule Pharmacokinetics Clinical Trials 133

ASPET

JULY 15, 2024

Mathematical modeling combining pharmacokinetics (PK) and toxicodynamics (TD) is a promising approach for optimizing dosing strategies and reducing toxicity. XELOX therapy, which comprises capecitabine and oxaliplatin, is the standard first-line chemotherapeutic regimen for colorectal cancer.

Pharmacokinetics 100

Pharmacokinetics Therapies Drugs Treatment 100

ASPET

MAY 22, 2024

In this review, we will examine what is currently known about CBC with regards to pharmacodynamics, pharmacokinetics, and receptor profile. While the cannabinoids share a common precursor molecule, cannabigerol, they are structurally and pharmacologically unique. These differences may engender differing therapeutic potentials.

Pharmacokinetics 185

Pharmacokinetics Disease Production Research 185

Covalent Modifiers

JANUARY 29, 2024

However, a majority of reported GPX4 inhibitors utilize chloroacetamide as a reactive electrophilic warhead, and the selectivity and pharmacokinetic properties still need to be improved. Thus, there is a broad interest in the development of GPX4 inhibitors.

Therapies 173

Therapies Pharmacokinetics Treatment 173

Drug Target Review

MARCH 24, 2025

Promising areas for AI implementation When discussing the most transformative AI applications in drug discovery, Sujeegar identifies a particularly ambitious goal: developing AI models that can simulate human pharmacokinetics and pharmacodynamics (PK/PD) using only preliminary laboratory data.

Clinical Trials 59

Clinical Trials Animal Testing Pharmacokinetics Drugs 59

Covalent Modifiers

JUNE 5, 2023

Finally, in vivo pharmacokinetic studies indicated that the agent was long-lived and orally bioavailable. We also compared the cellular efficacy of the agent in two-dimensional (2D) and three-dimensional (3D) cell cultures, side by side with the clinical candidate reversible IAP inhibitor LCL161.

Pharmacokinetics 130

Pharmacokinetics 130

Broad Institute

JULY 17, 2024

Together, the tools estimate how a drug may impact diverse outcomes of interest to drug developers: general cellular health, pharmacokinetics, and heart and liver function. Drug developers also assess pharmacokinetic effects, or how an organism absorbs, distributes, metabolizes, and clears a drug.

Pharmacokinetics 124

Pharmacokinetics Molecular Biology Drugs FDA 124

Covalent Modifiers

MARCH 13, 2024

Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV.

Pharmacokinetics 162

Pharmacokinetics Virus Treatment Drugs 162

Alta Sciences

AUGUST 16, 2023

Microsampling for Pediatric Baricitinib Pharmacokinetics shajjar Wed, 08/16/2023 - 19:06 Publication bio-2023-0044_3.pdf pdf Tags Bioanalysis Category Journal Article Weight 1

Pharmacokinetics 40

Pharmacokinetics 40

Alta Sciences

AUGUST 22, 2023

34 — Toxicokinetics, Pharmacokinetics, and Pharmacodynamics mecabana Tue, 08/22/2023 - 17:31 Publication the-altascientist-issue-34-toxicokinetics-pharmacokinetics-and-pharmacodynamics.pdf URL [link] Weight 1 Tags Research Support

Pharmacokinetics 40

Pharmacokinetics Research 40

Alta Sciences

AUGUST 22, 2023

34 — TOXICOKINETICS, PHARMACOKINETICS, AND PHARMACODYNAMICS mecabana Tue, 08/22/2023 - 17:31 Publication the-altascientist-issue-34-toxicokinetics-pharmacokinetics-and-pharmacodynamics.pdf URL [link] Weight 1 Tags Manufacturing and Analytical Services

Pharmacokinetics 40

Pharmacokinetics 40

ASPET

SEPTEMBER 28, 2023

These protocols were then used to determine the plasma pharmacokinetics of agmatine and the extent of distribution to the CNS. Upon application of this protocol to pharmacokinetic study, IV agmatine showed a half-life in plasma ranging between 18.9 The protocol also adequately withstood stability and dilution conditions.

Pharmacokinetics 100

Pharmacokinetics FDA Therapies Drugs 100

ASPET

AUGUST 8, 2024

Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few FDA-approved drugs that exhibit atropisomerism.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics FDA Approval Virus 100

Drug Patent Watch

DECEMBER 10, 2024

The Importance of Scientific Expertise Generic drug development involves a deep understanding of the scientific principles underlying drug development, including pharmacology, pharmacokinetics, and bioequivalence. Scientific experts in these fields are critical in ensuring that generic drugs are developed to meet the required standards.

Drug Development 98

Drug Development Pharmacokinetics Compliance Drugs 98

ASPET

JUNE 27, 2024

Furthermore, we evaluated the in vivo pharmacokinetics of the analogs following single dose IV and oral administration. Surprisingly, and at odds with their pharmacokinetic and in vitro human activity data, most analogs potently induced uterotrophic effects in estrogen-naïve female mice.

Pharmacokinetics 100

Pharmacokinetics Drug Development Disease Drugs 100

Drug Patent Watch

OCTOBER 30, 2023

Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical… The post Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma appeared (..)

Pharmacokinetics 111

Pharmacokinetics Drugs 111

ASPET

SEPTEMBER 12, 2023

This first-in-human, randomized, double-blind, placebo-controlled study (NCT04497662) evaluated safety, pharmacokinetics, receptor occupancy, and pharmacodynamics of the humanized anti-CD40 monoclonal antibody KPL-404. Nonlinear dose-dependent changes in various pharmacokinetic parameters were identified following the range of IV doses.

Pharmacokinetics 100

Pharmacokinetics Immune Response Trials Clinical Trials 100

Covalent Modifiers

SEPTEMBER 19, 2023

The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. RESULTS A total of 137 patients (60 with non–small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib.

Pharmacokinetics 147

Pharmacokinetics DNA Treatment 147

ASPET

SEPTEMBER 16, 2024

Acknowledging the potential for inter-species differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited.

Pharmacogenetics 100

Pharmacogenetics DNA Treatment Pharmacokinetics 100

ASPET

SEPTEMBER 7, 2023

The DDI covered in this review include pharmacokinetic DDI arising from enzyme inhibition or induction, primarily due to inhibition of cytochrome p450 enzymes (CYPs). This review focuses on the current knowledge of common opioid drug-drug interactions (DDI), focusing specifically on hydrocodone, oxycodone, and morphine DDI.

Pharmacokinetics 100

Pharmacokinetics Drugs Treatment Disease 100

ASPET

SEPTEMBER 16, 2024

PF-06952229 (MDV6058) selected using rational drug design is a potent and selective TGFβRI inhibitor (TGFβRIi) with a relatively clean off-target selectivity profile and good pharmacokinetic properties across species.

Pharmacokinetics 100

Pharmacokinetics Packaging Drugs 100

ASPET

OCTOBER 24, 2023

The pharmacokinetic and pharmacodynamic properties of orally administered BBP-671 evaluated in cannulated rats showed that CoA concentrations were elevated in blood, liver and brain. This work describes the pharmacokinetic/pharmacodynamic properties of BBP-671, a pantothenate kinase activator.

Metabolic Stability 100

Metabolic Stability Pharmacokinetics Regulations Drugs 100

Drug Patent Watch

DECEMBER 30, 2024

Key Requirements for Generic Drug Approval Bioequivalence Studies : The PMDA requires bioequivalence studies to ensure that the generic drug is equivalent to the RLD in terms of its pharmacokinetic and pharmacodynamic properties.

Drug Development 52

Drug Development Clinical Pharmacology Clinical Trials Pharmaceutical Companies 52

SCIENMAG: Medicine & Health

NOVEMBER 1, 2023

A small clinical trial with a pharmacokinetic sub-study, led by a world-renowned pharmacologist at the University of Houston, has demonstrated the promising effectiveness of the drug Riluzole for improving functionality in people with acute spinal cord injuries (SCI) if the drug is taken within 12 hours post-injury.

Clinical Trials 86

Clinical Trials Trials Pharmacokinetics Drugs 86

Chemical Biology and Drug Design

DECEMBER 19, 2024

ADMET prediction analysis indicated that compounds 5h and 5k showed good pharmacokinetic properties. Investigation of the mechanism of action indicated that 5k down-regulated NF-B expression, possibly by suppressing LPS-induced expression of the p65 protein.

Pharmacokinetics 100

Pharmacokinetics Regulations Treatment Drugs 100

Alta Sciences

JUNE 24, 2023

Design and Validation of a Bioanalytical Method to Support a Clinical Pharmacokinetic Study Involving the Use of Multiple Lots of the Biological Therapeutic Drug lperez Sat, 06/24/2023 - 08:07 Publication Altasciences_WRIB_2023_Design_and_Validation_of_a_Bioanalytical_Method_to_Support_a_Clinical_Pharmacokinetic_Study.pdf Tags Bioanalysis Date of publication (..)

Pharmacokinetics 40

Pharmacokinetics Drugs 40

Chemical Biology and Drug Design

AUGUST 18, 2024

The drug-like properties (like pharmacokinetics and pharmacodynamics) of the individual scaffolds can be improved by benzimidazole–oxadiazole chimeric molecules via a molecular hybridisation approach. Benzimidazole and oxadiazole cores can either be fused or incorporated using either functional groups/bonds.

Pharmacokinetics 100

Pharmacokinetics Drugs Research 100

The Pharma Data

NOVEMBER 17, 2020

The study demonstrated favorable proof-of-concept for LYT-100’s tolerability and pharmacokinetic (PK) profile, which will also enable twice-a-day (BID) dosing of LYT-100 in future studies.

Pharmacokinetics 52

Pharmacokinetics Treatment Trials Production 52

ASPET

OCTOBER 23, 2024

Neither nimodipine nor NP10679 alter each other's pharmacokinetic profile, suggesting no obvious drug-drug interactions. We found that NP10679 produced durable improvement of behavioral deficits in a well-characterized murine model of SAH, and these effects were greater than those produced by nimodipine alone, the current standard of care.

Clinical Development 100

Clinical Development Treatment Pharmacokinetics Drugs 100

ASPET

JUNE 27, 2024

Secondary VAS and pharmacokinetic (PK) endpoints and adverse events were assessed. Three doses of lenabasum (20, 60, and 120mg) were compared to placebo, and nabilone (3 and 6mg). The primary endpoint was the peak effect (Emax) on a bipolar Drug Liking visual analog scale (VAS). Results : Lenabasum was safe and well tolerated.

FDA Approval 100

FDA Approval Pharmacokinetics FDA Disease 100

Chemical Biology and Drug Design

MAY 31, 2023

Finally, in silico results and pharmacokinetic parameters of ADME showed that these compounds have good oral bioavailability properties. According to the docking result, the most stable conformation of AChE and compound 3i showed that it has a binding affinity of −10.82 kcal/moL.

Pharmacokinetics 100

Pharmacokinetics Research 100

Chemical Biology and Drug Design

JANUARY 29, 2024

In-silico ADME studies significant values of pharmacokinetic parameters and demonstrated good drug like characteristics based on Lipinski's rule of five. In addition, the QSTR study of new compounds were carried out with the help of Toxicity Estimation Software Tool (T.E.S.T). The results showed slight toxic nature of new compounds.

Pharmacokinetics 100

Pharmacokinetics Production Drugs Research 100